This is a phase 1, open-label study in healthy adults. This study is aimed at evaluating the safety, tolerability, and pharmacokinetics of ASC43F, a fixed-dose combination (FDC) and single dose tablet containing ASC41, a THR β agonist and ASC42, an FXR agonist in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
8
One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
8307 Gault Lane
San Antonio, Texas, United States
Safety and tolerability of ASC43F evaluated by incidence of treatment emergent adverse events (TEAEs).
Time frame: Baseline to day 7
To evaluate the pharmacokinetics as assessed by Cmax (Max Concentration) of ASC43F tablet following a single fixed oral dose in healthy subjects
Time frame: Baseline to day 4
To evaluate the pharmacokinetics as assessed by Area Under the Curve (AUC) of ASC43F tablet following a single fixed oral dose in healthy subjects
Time frame: Baseline to day 4
To evaluate the pharmacokinetics as assessed by Tmax (Time to Max Concentration) of ASC43F tablet following a single fixed oral dose in healthy subjects
Time frame: Baseline to day 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.